<DOC>
	<DOCNO>NCT01454323</DOCNO>
	<brief_summary>Phase II clinical trial include patient diagnose chronic anterior myocardial infarction ( 6 month acute phase complete revascularization assess evolution leave ventricular function patient monitor basal condition . Included patient study following condition : - Basal condition : define immediately precede administration cell therapy treatment . - Monitoring Condition 1 : three month drug administration cell therapy . Includes non-invasive method exploration ventricular function . - Monitoring Condition 2 : six month administration treatment . Includes method exploration ventricular function practise basal condition , include cardiac catheterism well non invasive method . - Monitoring Condition 3 : twelve month administration cell therapy drug . Includes non-invasive method exploration ventricular function . The trial hypothesis propose consist mononuclear cell bone marrow provide progenitor cell regenerative capacity also secrete several angiogenic factor , implantation ischemic tissue contribute element angiogenesis tissue regeneration myocardial functional recovery</brief_summary>
	<brief_title>Intracoronary Infusion Bone Marrow Mononuclear Cells Patients With Previous Myocardial Infarction .</brief_title>
	<detailed_description>This uncontrolled study efficacy cell therapy drug measure compare variable ventricular function treatment basal condition prior application The total number patient study 20 . The study population correspond male female patient chronic anterior myocardial infarction ( 6 month acute episode ) ventricular dysfunction . It expect 36 month inclusion one year follow Patients receive concomitant way drug treatment establish good practice , would certainly possible improvement occurs due drug treatment . It study patient population gender age 18 80 year diagnose Chronic anterior myocardial infarction ( 6 month acute phase complete revascularization ) . Objectives study : - Main objective : To determine efficacy intracoronary injection adult stem cell autologous bone marrow patient chronic anterior myocardial infarction term improvement ventricular function , determine hemodynamic , echocardiographic New York Heart Association ( NYHA ) functional class criterion , result improvement heart failure symptom quality life 's patient . - Secondary objective : 1 . To investigate basic cellular mechanism underlie myocardial regeneration process correlation hemodynamic criterion ventricular function improvement biologicals correspond composition functionality infuse cell . 2 . To analyze clinical , hemodynamic biologicals factor able influence favorably great degree functional recovery regenerative treatment chronic myocardial infarction . 3 . To design , view result obtain , suitable protocol application cell therapy treat patient old anterior infarction , term ideal characteristic medullary graft term patient likely beneficiary , order establish definitive strategy include cell therapy standard treatment disease near future provide result indicate . The primary variable improvement ventricular function monitoring angiographic echocardiographic parameter .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>1 . Aged 18 80 year . 2 . Patients diagnose Chronic anterior myocardial infarction ( 6 month acute episode ) symptoms / sign heart failure . 3 . Left ventricular ejection fraction ( LVEF ) &lt; 45 % distensibility change . 4 . Complete revascularization perform least 6 month infusion cell . 1 . Patients active wait list heart transplantation.. 2 . Treatable patient resynchronization . 3 . Patients 80 year 4 . Coexistence serious systemic disease . 5 . Active infection , HIV , Hepatitis B Hepatitis C. 6 . Patients malignant premalignant tumour . 7 . Coexistence haematological disease . 8 . Pregnant woman , breastfeed period , childbearing potential age use effective contraception . 9 . Patients currently participate complete participation clinical trial period less three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Chronic Myocardial Ischemia</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Bone marrow mononuclear cell</keyword>
</DOC>